May 28 (Reuters) – The U.S. FDA’s advisory panel on Thursday voted in favor of recommending that COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant JN.1 lineage XFG variant.
Eight out of nine panel members voted in favor of the recommendation, while one abstained.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
